Brendon Neuen

Understanding Renal Outcomes in SURPASS-CVOT, With Sophia Zoungas, MBBS, PhD Podcast Episode · Kidney Compass: Navigating Clinical Trials · 2025-11-13 · 17m

In the last #KidneyKompass @brendonneuen.bsky.social chats with Sophia Zoungas podcasts.apple.com/ca/podcast/k... on the SURPASS data

G-force FTW @christosargyrop.bsky.social @rnflex.bsky.social

Hey @brianrifkin.bsky.social if sema is captopril what would you call dulaglutide? 😏

T0d: #NephJC

🛑Remission is defined an eGFR decline of ~1 ml/min/1.73 m²/year, closer to physiological rate

📉Vs 2-3 ml per year with only conservative therapy; hopefully, B-cell therapies will further flatten the slope

By @brendonneuen.bsky.social &Co

pubmed.ncbi.nlm.nih....

Kidney Week in Houston: Day 1 — NephJC in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis

16 is same as last year

someone check if I have missed anything

Read our blogs here www.nephjc.com/news/kidneyw...

#NephJC #KidneyWk

@nephroseeker.medsky.social @brendonneuen.bsky.social

OK thread of all simulpubs at this year's #KidneyWk

ORIGIN-3: Atacicept pubmed.ncbi.nlm.nih.gov/41196369/

CKD as a curable dz? www.kidney-international.org/article/S008...

Albuminuria as a surrogate endpoint www.nature.com/articles/s41...

Last year tally

Will we get more simultaneous publications this year than last year at #KidneyWk?

We had 16 last year

@brendonneuen.bsky.social
@nephroseeker.medsky.social

Will thread all later - but the #NephJC blog will have them all

SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria This meta-analysis examines whether estimated glomerular filtration rate or degree of albuminuria, as measured by urinary albumin to creatinine ratio, modifies the effects of sodium-glucose cotranspor...

And @brendonneuen.bsky.social with another simultaneous pub in @jama.com

jamanetwork.com/journals/jam...

Flozination by GFR/albuminuria

#KidneyWk

LBRO 2

In the afternoon another late breaking oral session among other things at 4:30 pm

@brendonneuen.bsky.social
Lorundrostat
A new oral GLP1
REMODEL to understand sema mechanism
GBD kidney disease with @paddymark.bsky.social
And
@cervantes-lily1.bsky.social !

#KidneyWk

Figure 1 Effect of empagliflozin versus placebo on study average concentration of urine biomarkers (indexed to urine creatinine). The MMRM model was adjusted for the prognostic variables specified in the minimized randomization algorithm (i.e., age, sex, prior diabetes, eGFR, uACR, and trial site region) in the same categories used in the minimization process, initial freezer storage temperature (-20°C versus below -20°C) and baseline log2-transformed urine biomarker-creatinine ratio. A weighted average of 2- and 18- month values proportional to the amount of time between visits was used to estimate the study average log2-transformed urine biomarker-to-creatinine ratio in each arm. Absolute values indicate geometric mean (approximate SE) creatinine-indexed urine biomarker concentration in the units specified. The size of the boxes represents the amount of information estimated.

Is it not really TGF - and something else in the tubules?

Fascinating Biomarker study in @ajkd.bsky.social from the EMPA-KIDNEY group

www.ajkd.org/article/S027...

cc @pranavgarimella.bsky.social

#NephSky #RevengeOfTheTubules

New episode of Freely Filtered with @brendonneuen.bsky.social @hswapnil.medsky.social @captainchloride.bsky.social @sophia-kidney.bsky.social and author Muth Vaduganathan discussing the CONVINCE trial

www.nephjc.com/freelyfilter...

With chapters, refs, and pictures

From the Lancet 2022 paper:

But I agree it is worth drilling down a bit more (it is on the to-do list)

LBRO 1

LBRO 2

LBRO 3

And three ‘late breaking research’ orals each evening Thursday - Saturday

#KidneyWk

HICT 2

A second High Impact trial session in plenary hall on Saturday AM

#KidneyWk

HICT 1

It’s all live now!

Apart from the two trials mentioned above

We have 5 more sessions at #KidneyWk + posters

High Impact Trials 1 on Friday AM in plenary hall

program for thursday at kidney wk including 2 LBCTs and Vlado P talking on RCTs and curing kidney disease

The opening plenary at #KidneyWk looks phenomenal

Renal RCT Renaissance is upon us

(LBCT list drops tomorrow)

www.asn-online.org/education/ki...

In this house we drink liquids and support #nephjc

(Maybe I should get a backpack next time)

Donate at: www.nephjc.com/news/2025/9/...

Take the ultimate deep dive in major recent clinical trials with the largest global gathering of clinical trials key stakeholders at #CVCT2025, December 8-10, 2025 in Washington DC ! Discover the scientific program here: www.globalcvctforum.com/scientific-p...
#clinicaltrials #clinicalresearch #CVCT

Join us December 8-10, Washington DC! Full programme here: www.globalcvctforum.com/scientific-p...

Interesting slide #BucketOfColdWater

📢 New in CJASN: pooled analysis of all completed phase 2/3 RCTs in #IgAN

🔹 4 drug classes (steroids, B-cell, complement, non-immunological)
🔹 All ↓ proteinuria ≥30%
🔹 All improved GFR slope
🔹 Biggest benefit: B-cell therapies

journals.lww.com/cjasn/abstra...

If you want to support #NephJC and get some cool merch, check out
www.nephjc.com/merch...

ASN Reveals Kidney Week Plenary Details | Docwire News The American Society of Nephrology announced details of the plenary sessions scheduled to take place at Kidney Week 2025, which will take place November 6-9, in Houston, Texas.

Attending Kidney Week 2025? Check out details about the plenaries. We'll be there, at Booth 2234! #kidneywk #nephrology #nephsky @asnkidney.bsky.social www.docwirenews.com/post/asn-rev...

Your abstract could be next to inspire change in kidney care. When you share your research at #ISNWCN, the benefits go far beyond the presentation.
• Global visibility
• Peer recognition
• Publication opportunity

Submit your abstract today ➡️ http://lite.spr.ly/6...

The HiLo Trial - Visual Abstract — NephJC Is a lower versus higher phosphate target beneficial to patients undergoing hemodialysis? Check out this crisp VA by Dr Sejal Lakhani

😎Check out the VA for HiLO by @sejalplakhani.bsky.social
🆒 This should be quite the discussion, don't miss it!
#NephJC #NephSky
www.nephjc.com/news/2025/8/4/the-hilo-trial-visual-abstract

Reduction in all-cause hospitalisation driven by fewer admissions for:
- Cardiac
- Renal
- Metabolic disorders, and
- Infections

Interestingly reduction in infections also observed with semaglutide in the FLOW trial - could GDMT improve physical resilience & susceptibility to infections?

🌏 Join us at WCN'26 in Yokohama!
🧠 Learn from global experts
📈 Share your research
👥 Connect with peers
📅 Abstracts due Oct 22
🎬 #ISNFilmEvent submissions by Nov 5
✈️ Travel grants & registration open Sept 16
🔗 http://lite.spr.ly/6... #ISNWCN

SGLT2i in CKD: impact beyond kidneys

🔻 15% all-cause hospitalizations
✅ Consistent regardless of eGFR, UACR & diabetes
🏥 ~36 fewer hospitalizations per 1000 pt-years

Large absolute gains for patients & health systems

Meta-analysis in @asnpublications.bsky.social

journals.lww.com/cjasn/pages/...

Good example of CV and kidney co primary outcome

Yeah I think that is the one way and probably the right approach, similar to what HF has done - ideally large enough numbers of patients receiving each component of GDMT #nephjc

Yep I'm not talking in the context of this study. I just need to pick the occasional argument with @kidneyboy.bsky.social to keep it interesting 😉 #nephjc

No denial to GDMT. Patients should be as well treated as possible, and then evaluate new therapies vs placebo on top of that. Mandating everyone is on RASi/SGLT2i/MRA/GLP-1 may reduce generalisability, as not all patients will tolerate or can access all 4 drugs